EE200100645A - Amüloidogeense haiguse preventsioon ja ravi - Google Patents

Amüloidogeense haiguse preventsioon ja ravi

Info

Publication number: EE200100645A
Authority: EE; Estonia
Prior art keywords: amyloid; prevention; treatment; fibril; disclosed
Prior art date: 1999-06-01

Application number

EEP200100645A

Other languages

English (en)

Inventor

B. Schenk Dale

Original Assignee

Neuralab Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-01

Filing date

2000-06-01

Publication date

2003-02-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22475417&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200100645(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-01 Application filed by Neuralab Limited filed Critical Neuralab Limited

2003-02-17 Publication of EE200100645A publication Critical patent/EE200100645A/et

2011-12-15 Publication of EE05492B1 publication Critical patent/EE05492B1/et

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Molecular Biology (AREA)
Neurology (AREA)
Urology & Nephrology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Mycology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Biophysics (AREA)
Food Science & Technology (AREA)

EEP200100645A 1999-06-01 2000-06-01 Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral EE05492B1 (et)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13701099P	1999-06-01	1999-06-01
PCT/US2000/015239 WO2000072876A2 (en)	1999-06-01	2000-06-01	Prevention and treatment of amyloidogenic disease

Publications (2)

Publication Number	Publication Date
EE200100645A true EE200100645A (et)	2003-02-17
EE05492B1 EE05492B1 (et)	2011-12-15

Family

ID=22475417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200100645A EE05492B1 (et)	1999-06-01	2000-06-01	Farmatseutilised kompositsioonid, nendega seotud meetodid ja nende kasutamine amloidogeensete haiguste korral

Country Status (31)

Country	Link
US (8)	US7977316B2 (et)
EP (2)	EP1185296B1 (et)
KR (3)	KR20090071673A (et)
CN (2)	CN101091795A (et)
AT (1)	ATE495755T1 (et)
AU (1)	AU5316300A (et)
BG (1)	BG65756B1 (et)
BR (1)	BR0011103A (et)
CA (1)	CA2375104C (et)
CY (1)	CY1111639T1 (et)
CZ (1)	CZ302971B6 (et)
DE (1)	DE60045550D1 (et)
EA (1)	EA200101250A1 (et)
EE (1)	EE05492B1 (et)
ES (2)	ES2362029T3 (et)
HK (1)	HK1045117B (et)
HR (1)	HRP20010893A2 (et)
HU (1)	HU229986B1 (et)
IL (3)	IL146563A0 (et)
IS (1)	IS2925B (et)
MX (1)	MXPA01012293A (et)
NO (1)	NO20015758L (et)
NZ (2)	NZ556622A (et)
PL (1)	PL202217B1 (et)
PT (1)	PT1185296E (et)
SG (2)	SG147275A1 (et)
SK (1)	SK288207B6 (et)
TR (1)	TR200103469T2 (et)
UA (1)	UA81216C2 (et)
WO (1)	WO2000072876A2 (et)
ZA (1)	ZA200109662B (et)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9706957D0 (en)	1997-04-05	1997-05-21	Smithkline Beecham Plc	Formulation
US8173127B2 (en) *	1997-04-09	2012-05-08	Intellect Neurosciences, Inc.	Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US6761888B1 (en)	2000-05-26	2004-07-13	Neuralab Limited	Passive immunization treatment of Alzheimer's disease
US6913745B1 (en)	1997-12-02	2005-07-05	Neuralab Limited	Passive immunization of Alzheimer's disease
US7588766B1 (en)	2000-05-26	2009-09-15	Elan Pharma International Limited	Treatment of amyloidogenic disease
US6787523B1 (en)	1997-12-02	2004-09-07	Neuralab Limited	Prevention and treatment of amyloidogenic disease
US6905686B1 (en)	1997-12-02	2005-06-14	Neuralab Limited	Active immunization for treatment of alzheimer's disease
US7179892B2 (en)	2000-12-06	2007-02-20	Neuralab Limited	Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en)	1998-04-07	2008-02-28	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en)	1998-04-07	2010-09-07	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
US20030147882A1 (en)	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
GB9820525D0 (en)	1998-09-21	1998-11-11	Allergy Therapeutics Ltd	Formulation
NZ513935A (en)	1999-02-17	2004-02-27	Csl Ltd	Immunogenic complexes and methods relating thereto
US6787637B1 (en)	1999-05-28	2004-09-07	Neuralab Limited	N-Terminal amyloid-β antibodies
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
IL149976A0 (en)	1999-12-08	2002-12-01	Mindset Biopharmaceuticals Usa	Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
GB0000891D0 (en) *	2000-01-14	2000-03-08	Allergy Therapeutics Ltd	Formulation
DE1257584T1 (de)	2000-02-24	2003-05-28	Lilly Co Eli	Humanisierte antikörper, die amyloid beta peptid demarkieren
CA2404237C (en) *	2000-04-05	2010-01-26	University Of Tennessee Research Corporation	Methods of investigating, diagnosing, and treating amyloidosis
AU2007200047B2 (en) *	2000-07-07	2009-11-26	Bioarctic Neuroscience Ab	Prevention and treatment of Alzheimer's disease
EP2082749A3 (en)	2000-07-07	2010-06-30	Bioarctic Neuroscience AB	Prevention and treatment of Alzheimer's disease
US7700751B2 (en)	2000-12-06	2010-04-20	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize β-amyloid peptide
PE20020574A1 (es)	2000-12-06	2002-07-02	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido amiloideo beta
AU2002257162A1 (en)	2001-04-30	2002-11-11	Eli Lilly And Company	Humanized antibodies
AU2002258808A1 (en)	2001-04-30	2002-11-11	Eli Lilly And Company	Humanized antibodies
US6906169B2 (en) *	2001-05-25	2005-06-14	United Biomedical, Inc.	Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
DK1944040T3 (da)	2001-08-17	2012-10-29	Univ Washington	Analysefremgangsmåde for Alzheimers sygdom
US20050227941A1 (en) *	2001-12-17	2005-10-13	Karen Duff	Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
CA2471092A1 (en)	2001-12-21	2003-07-10	Antigenics Inc.	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
MY139983A (en)	2002-03-12	2009-11-30	Janssen Alzheimer Immunotherap	Humanized antibodies that recognize beta amyloid peptide
CA2493119A1 (en) *	2002-07-17	2004-01-22	Mindset Biopharmaceuticals Usa Inc.	Peptides and methods of screening immunogenic peptide vaccines against alzheimer's disease
US20070213512A1 (en) *	2002-10-01	2007-09-13	Krafft Grant A	Amyloid beta peptide analogs and assemblies thereof
US9034337B2 (en)	2003-10-31	2015-05-19	Prothena Biosciences Limited	Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) *	2002-11-01	2005-03-16	Elan Pharm Inc	Prevention and treatment of synucleinopathic disease
US8506959B2 (en)	2002-11-01	2013-08-13	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
US8697082B2 (en)	2002-11-01	2014-04-15	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en)	2003-10-31	2008-01-17	Elan Pharmaceuticals, Inc.	Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ATE468886T1 (de)	2003-02-10	2010-06-15	Applied Molecular Evolution	Abeta-bindende moleküle
US8663650B2 (en)	2003-02-21	2014-03-04	Ac Immune Sa	Methods and compositions comprising supramolecular constructs
ES2246177B1 (es) *	2003-05-08	2007-03-01	Universidad De Zaragoza.	Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
HUE035044T2 (en)	2003-05-19	2018-05-02	Prothena Biosciences Ltd	Truncated fragments of alpha-synuclein in Lewy-body disease
US7358331B2 (en)	2003-05-19	2008-04-15	Elan Pharmaceuticals, Inc.	Truncated fragments of alpha-synuclein in Lewy body disease
PE20050627A1 (es)	2003-05-30	2005-08-10	Wyeth Corp	Anticuerpos humanizados que reconocen el peptido beta amiloideo
US7807171B2 (en)	2003-07-25	2010-10-05	Ac Immune Sa	Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
US7674599B2 (en)	2003-11-08	2010-03-09	Elan Pharmaceuticals, Inc.	Methods of using antibodies to detect alpha-synuclein in fluid samples
WO2005080435A1 (ja)	2004-02-20	2005-09-01	Immuno-Biological Laboratories Co., Ltd.	モノクローナル抗体およびその利用
SE0401601D0 (sv)	2004-06-21	2004-06-21	Bioarctic Neuroscience Ab	Protofibril specific antibodies and uses thereof
AU2005290250A1 (en)	2004-07-30	2006-04-06	Rinat Neuroscience Corp.	Antibodies directed against amyloid-beta peptide and methods using same
MX2007001679A (es)	2004-08-09	2007-05-23	Elan Pharm Inc	Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
PE20061329A1 (es)	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
US7625560B2 (en)	2004-12-15	2009-12-01	Janssen Alzheimer Immunotherapy	Humanized antibodies that recognize beta amyloid peptide
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
ME01826B (me) *	2005-11-30	2014-12-20	Abbvie Inc	MONOKLONALNA ANTITELA PROTIV AMILOIDNOG BETA PROTEINA l NJIHOVA UPOTREBA
JP5475994B2 (ja)	2005-11-30	2014-04-16	アッヴィ・インコーポレイテッド	抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
KR101439828B1 (ko)	2005-11-30	2014-09-17	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
NO347079B1 (no)	2006-03-23	2023-05-08	Bioarctic Neuroscience Ab	Forbedrede protofibrilselektive antistoffer og anvendelse derav
US8784810B2 (en)	2006-04-18	2014-07-22	Janssen Alzheimer Immunotherapy	Treatment of amyloidogenic diseases
AU2007301981A1 (en) *	2006-09-25	2008-04-03	Universiteit Maastricht	Means and methods for diagnosing and/or treating a subject at risk of developing heart failure
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP3239174A1 (en)	2007-01-05	2017-11-01	University of Zurich	Anti-beta-amyloid antibody and uses thereof
HRP20140049T1 (hr)	2007-01-05	2014-02-28	University Of Zürich	Anti beta-amiloid antitijela i njihova upotreba
US8147833B2 (en)	2007-02-23	2012-04-03	Neotope Biosciences Limited	Prevention and treatment of synucleinopathic and amyloidogenic disease
CA2678963C (en)	2007-02-23	2018-05-01	Elan Pharmaceuticals, Inc.	Prevention and treatment of synucleinopathic and amyloidogenic disease
ES2570182T3 (es)	2007-02-23	2016-05-17	Prothena Biosciences Ltd	Prevención y tratamiento de la enfermedad sinucleinopática y amiloidogénica
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
US8003097B2 (en)	2007-04-18	2011-08-23	Janssen Alzheimer Immunotherapy	Treatment of cerebral amyloid angiopathy
EP2149584B1 (en) *	2007-04-20	2017-12-13	The Chemo-Sero-Therapeutic Research Institute	Method for enhancing immune response with peptide
SI2182983T1 (sl)	2007-07-27	2014-09-30	Janssen Alzheimer Immunotherapy	Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
EP2175879A4 (en) *	2007-08-09	2010-09-22	Sylvan Pharmaceuticals Pty Ltd	TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
EP2282758B1 (en)	2008-04-29	2018-11-21	BioArctic AB	Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
JP5810413B2 (ja)	2008-12-19	2015-11-11	バイオジェンインターナショナルニューロサイエンスゲーエムベーハー	ヒト抗アルファシヌクレイン自己抗体
DK2539366T3 (en)	2010-02-26	2018-02-05	Bioarctic Neuroscience Ab	PROTOFIBRIL-BINDING ANTIBODIES AND THEIR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR PARKINSON'S DISEASE, DEMENS WITH LEWY BODY AND OTHER ALPHA SYNUCLEINOPATHIES
KR20110111594A (ko) *	2010-04-05	2011-10-12	서울대학교산학협력단	알파-시뉴클레인 유래 곱슬 아밀로이드 섬유의 제조방법, 이를 이용한 하이드로젤의 제조 방법 및 그 이용 방법
ES2684475T3 (es)	2010-04-15	2018-10-03	Abbvie Inc.	Proteínas que se unen a beta amiloide
EP2575859B1 (en) *	2010-06-03	2018-09-19	Ramot at Tel Aviv University, Ltd.	Methods of treating diabetes and compositions capable of same
CN102311499A (zh) *	2010-07-09	2012-01-11	博生吉医药科技(苏州)有限公司	一种癌症治疗用人源化单克隆抗体及其制备及应用
EP3527220A1 (en)	2010-08-12	2019-08-21	AC Immune S.A.	Vaccine engineering
EP3533803B1 (en)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antibodies
CA2813833C (en)	2010-10-26	2020-09-22	Ac Immune S.A.	Liposome-based construct comprising a peptide modified through hydrophobic moieties
AU2012265320B2 (en) *	2011-06-01	2016-11-03	Xiamen Innovax Biotech Co. Ltd.	Fusion protein comprising diphtheria toxin non-toxic mutant CMR197 or fragment thereof
HUE041391T2 (hu)	2011-06-23	2019-05-28	Biogen Int Neuroscience Gmbh	Anti-alfa-szinukleinkötõ molekulák
DK2579042T3 (da)	2011-10-04	2014-07-21	Affiris Ag	Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
JP6628786B2 (ja)	2014-07-10	2020-01-15	バイオアークティックアーベー	改善されたＡβプロトフィブリル結合抗体
CN105616405B (zh) *	2014-11-05	2021-05-07	中国人民解放军第三军医大学第三附属医院	依达拉奉在制备用于预防和治疗脑淀粉样血管病的药物中的应用
MA41115A (fr)	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	Procédé de traitement de la maladie d'alzheimer
US10633433B2 (en)	2015-01-28	2020-04-28	Prothena Biosciences Limited	Anti-transthyretin antibodies
US10464999B2 (en)	2015-01-28	2019-11-05	Prothena Biosciences Limited	Anti-transthyretin antibodies
US9879080B2 (en)	2015-01-28	2018-01-30	Prothena Biosciences Limited	Anti-transthyretin antibodies
EP3070096A1 (en) *	2015-03-19	2016-09-21	Ludwig-Maximilians-Universität München	A peptide or collection of peptides derived from amyloid precursor protein
CA3004494A1 (en)	2015-11-09	2017-05-18	The University Of British Columiba	Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
KR20180094876A (ko)	2015-11-09	2018-08-24	더 유니버시티 오브 브리티쉬 콜롬비아	아밀로이드 베타 에피토프 및 이에 대한 항체
US10772969B2 (en)	2015-11-09	2020-09-15	The University Of British Columbia	N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US10265497B2 (en) *	2015-11-24	2019-04-23	Massachusetts Institute Of Technology	Systems and methods for treating dementia
AU2017299858B2 (en)	2016-07-18	2024-07-25	Promis Neurosciences, Inc.	Antibodies to Amyloid beta
US20180125920A1 (en)	2016-11-09	2018-05-10	The University Of British Columbia	Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CA3044440A1 (en)	2016-11-17	2018-05-24	Cognito Therapeutics, Inc.	Methods and systems for neural stimulation via visual stimulation
JP2020526191A (ja)	2017-06-29	2020-08-31	ザトラスティーズオブコロンビアユニバーシティインザシティオブニューヨークＴｈｅＴｒｕｓｔｅｅｓＯｆＣｏｌｕｍｂｉａＵｎｉｖｅｒｓｉｔｙＩｎＴｈｅＣｉｔｙＯｆＮｅｗＹｏｒｋ	アミロイド沈着疾患を治療するためのキメラ抗体
US12286469B2 (en)	2017-07-18	2025-04-29	The University Of British Columbia	Humanized antibodies binding to amyloid-beta (A-beta)
EP3658172A4 (en)	2017-07-25	2021-05-05	TrueBinding, Inc.	TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
US11382974B2 (en) *	2017-08-01	2022-07-12	The Trustees Of Columbia University In The City Of New York	Methods and compositions for treatment of amyloid deposition diseases
WO2019040612A1 (en)	2017-08-22	2019-02-28	Biogen Ma Inc.	PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA-AMYLOID ANTIBODIES
EP3691447A4 (en)	2017-10-06	2021-08-11	Prothena Biosciences Limited	ANTI-TRANSTHYRETINE ANTIBODY
MX2020003043A (es)	2017-10-06	2020-10-05	Prothena Biosciences Ltd	Métodos para detectar transtiretina.
US10960225B2 (en)	2017-10-10	2021-03-30	Massachusetts Institute Of Technology	Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function
AU2018347870B2 (en)	2017-10-10	2022-12-08	Massachusetts Institute Of Technology	Systems and methods for preventing, mitigating, and/or treating dementia
MX2020005433A (es)	2017-11-29	2020-08-27	Prothena Biosciences Ltd	Formulacion liofilizada de un anticuerpo monoclonal contra la transtirretina.
GB201720970D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Antibodies
GB201720975D0 (en)	2017-12-15	2018-01-31	Ucb Biopharma Sprl	Anti-alpha synuclein antibodies
US12018069B2 (en)	2018-06-28	2024-06-25	The Trustees Of Columbia University In The City Of New York	Methods and compositions for imaging amyloid deposits
CN115359999A (zh)	2018-11-02	2022-11-18	台达电子企业管理（上海）有限公司	变压器模块及功率模块
US20210400932A1 (en) *	2018-11-09	2021-12-30	Neurimmune Ag	Patient-derived amyloid xenograft non-human animal model
CN120058944A (zh)	2019-01-30	2025-05-30	真和制药有限公司	抗gal3抗体及其用途
KR102135130B1 (ko) *	2019-02-15	2020-07-17	충북대학교 산학협력단	트랜스타이레틴 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도
MX2022014786A (es)	2020-05-26	2023-01-16	Truebinding Inc	Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN116528888A (zh) *	2020-10-30	2023-08-01	拉什大学医学中心	用于治疗阿尔兹海默症的鼻内免疫疗法
CN115475247B (zh) *	2021-06-16	2024-02-20	厦门大学	β2-微球蛋白或其抑制剂的制药用途
CA3239708A1 (en) *	2021-12-03	2023-06-08	Aubin MICHALON	Novel potency assay for antibody-based drugs and useful means therefor
TWI824398B (zh) *	2022-01-27	2023-12-01	慈濟學校財團法人慈濟大學	一種肌動蛋白重組調節物之抑制劑用於製備治療睡眠剝奪引起之記憶退化之藥物之用途
EP4630812A1 (en) *	2022-12-05	2025-10-15	Neurimmune AG	Cyclic compounds and their use in assays for detecting antibodies

Family Cites Families (203)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US573547A (en) *		1896-12-22		smith
US73655A (en) *		1868-01-21		Improvement in safety-pockets
US14692A (en) *		1856-04-15		Improved diaphragm fluid-meter
CH652145A5 (de)	1982-01-22	1985-10-31	Sandoz Ag	Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4443427A (en)	1982-06-21	1984-04-17	Sidney Farber Cancer Institute, Inc.	Monoclonal antibody
US4634666A (en)	1984-01-06	1987-01-06	The Board Of Trustees Of The Leland Stanford Junior University	Human-murine hybridoma fusion partner
US5208036A (en)	1985-01-07	1993-05-04	Syntex (U.S.A.) Inc.	N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en)	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
EP0236509B1 (en)	1985-09-19	1993-02-10	Toray Industries, Inc.	B2-microglobulin-removing column
US4641473A (en) *	1985-12-23	1987-02-10	Trezza Ronald F	Clip construction for wall arrangement
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5231170A (en)	1986-08-27	1993-07-27	Paul Averback	Antibodies to dense microspheres
GB8625435D0 (en) *	1986-10-23	1986-11-26	Erba Farmitalia	Human apolipoprotein ai
US5187153A (en)	1986-11-17	1993-02-16	Scios Nova Inc.	Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5220013A (en)	1986-11-17	1993-06-15	Scios Nova Inc.	DNA sequence useful for the detection of Alzheimer's disease
US5290762A (en) *	1986-12-24	1994-03-01	John Lezdey	Treatment of inflammation
DE3702789A1 (de)	1987-01-30	1988-08-18	Bayer Ag	Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins
EP0279582A3 (en)	1987-02-17	1989-10-18	Pharming B.V.	Dna sequences to target proteins to the mammary gland for efficient secretion
GB8720115D0 (en) *	1987-08-26	1987-09-30	Cooper G J S	Treatment of diabetes mellitus
US4883666A (en) *	1987-04-29	1989-11-28	Massachusetts Institute Of Technology	Controlled drug delivery system for treatment of neural disorders
US5229490A (en)	1987-05-06	1993-07-20	The Rockefeller University	Multiple antigen peptide system
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US5583112A (en)	1987-05-29	1996-12-10	Cambridge Biotech Corporation	Saponin-antigen conjugates and the use thereof
US5641474A (en)	1987-06-24	1997-06-24	Autoimmune, Inc.	Prevention of autoimmune diseases by aerosol administration of autoantigens
US5645820A (en)	1987-06-24	1997-07-08	Autoimmune, Inc.	Treatment of autoimmune diseases by aerosol administration of autoantigens
US5849298A (en)	1987-06-24	1998-12-15	Autoimmune Inc.	Treatment of multiple sclerosis by oral administration of bovine myelin
US5869054A (en)	1987-06-24	1999-02-09	Autoimmune Inc.	Treatment of multiple sclerosis by oral administration of autoantigens
EP0666080B1 (en)	1987-06-24	2004-01-21	Brigham & Women's Hospital	Treatment of autoimmune diseases by oral administration of autoantigens
US5571500A (en)	1987-06-24	1996-11-05	Autoimmune, Inc.	Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en)	1987-06-24	1996-11-05	Autoimmune, Inc.	Treatment of autoimmune diseases by aerosol administration of autoantigens
US5004697A (en)	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
US5231000A (en)	1987-10-08	1993-07-27	The Mclean Hospital	Antibodies to A4 amyloid peptide
CA1339014C (en)	1987-10-08	1997-03-25	Ronald E. Majocha	Antibodies to a4 amyloid peptide
AU2728588A (en)	1987-10-23	1989-05-23	Genetics Institute Inc.	Composition and method for treating cancers characterized by over-expression of the c-fms proto-oncogene
US5266561A (en) *	1988-01-11	1993-11-30	Amylin Pharmaceuticals, Inc.	Treatment of type 2 diabetes mellitus
AU3056289A (en)	1988-01-13	1989-08-11	Mclean Hospital Corporation, The	Genetic constructs containing the alzheimer brain amyloid gene
US5785973A (en) *	1988-02-01	1998-07-28	Praxis Biologics, Inc.	Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines
US4912094B1 (en)	1988-06-29	1994-02-15	Ribi Immunochem Research Inc.	Modified lipopolysaccharides and process of preparation
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2006700A1 (en)	1989-01-17	1990-07-17	Antonello Pessi	Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1990012870A1 (en)	1989-04-14	1990-11-01	Research Foundation For Mental Hygiene, Inc.	Monoclonal antibody to amyloid peptide
AU5439790A (en)	1989-04-14	1990-11-16	Research Foundation For Mental Hygiene, Inc.	Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
HU212924B (en)	1989-05-25	1996-12-30	Chiron Corp	Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en)	1989-06-14	1995-03-21	The United States Of America As Represented By The Department Of Health And Human Services	Gene therapy
US5262303A (en)	1989-10-13	1993-11-16	Trustees Of Boston University	Ligand/anti-ligand assays for adherent proteins
IT1237764B (it)	1989-11-10	1993-06-17	Eniricerche Spa	Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5633076A (en)	1989-12-01	1997-05-27	Pharming Bv	Method of producing a transgenic bovine or transgenic bovine embryo
HUT61487A (en)	1989-12-20	1993-01-28	Brigham & Womens Hospital	Process for producing aerosol pharmaceutical composition comprising autoantigens
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
EP0594607B1 (en)	1990-03-02	1997-08-27	Autoimmune, Inc.	Enhancement of the down-regulation of autoimmune diseases by oral or enteral administration of autoantigens
US5279833A (en)	1990-04-04	1994-01-18	Yale University	Liposomal transfection of nucleic acids into animal cells
EP0451700A1 (en)	1990-04-10	1991-10-16	Miles Inc.	Recombinant APP minigenes for expression in transgenic mice as models for Alzheimers's disease
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
WO1991016628A1 (en)	1990-04-24	1991-10-31	The Regents Of The University Of California	Purification, detection and methods of use of protease nexin-2
US5753624A (en)	1990-04-27	1998-05-19	Milkhaus Laboratory, Inc.	Materials and methods for treatment of plaquing disease
CA2081482C (en)	1990-04-27	2000-11-21	Ellis L. Kline	Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
AU8081491A (en)	1990-06-01	1991-12-31	Cetus Corporation	Compositions and methods for identifying biologically active molecules
US5593970A (en)	1990-06-11	1997-01-14	Biochem Pharma Inc.	Heterocyclic anthracycline analogs
ATE260974T1 (de)	1990-06-15	2004-03-15	Scios Inc	Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt
ATE185601T1 (de)	1990-07-10	1999-10-15	Cambridge Antibody Tech	Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5780587A (en)	1990-08-24	1998-07-14	President And Fellows Of Harvard College	Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5877397A (en)	1990-08-29	1999-03-02	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en)	1990-08-29	1998-08-04	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en)	1990-08-29	1999-02-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JP2938569B2 (ja)	1990-08-29	1999-08-23	ジェンファームインターナショナル，インコーポレイティド	異種免疫グロブリンを作る方法及びトランスジェニックマウス
NZ239643A (en) *	1990-09-17	1996-05-28	North American Vaccine Inc	Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2092823A1 (en)	1990-09-28	1992-03-29	Barry D. Greenberg	Transgenic animals with alzheimer's amyloid precursor gene
JP2635444B2 (ja)	1990-10-15	1997-07-30	オートイミューンインク	自己抗体の経口投与による自己免疫性疾患の治療
US5877015A (en)	1991-01-21	1999-03-02	Imperial College Of Science, Technology Of Medicine	APP770 mutant in alzheimer's disease
US5192753A (en)	1991-04-23	1993-03-09	Mcgeer Patrick L	Anti-rheumatoid arthritic drugs in the treatment of dementia
US5858657A (en)	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
US5871907A (en)	1991-05-15	1999-02-16	Medical Research Council	Methods for producing members of specific binding pairs
JP4124480B2 (ja)	1991-06-14	2008-07-23	ジェネンテック・インコーポレーテッド	免疫グロブリン変異体
US5672805A (en)	1991-07-18	1997-09-30	The Regents Of The University Of California	Transgenic mice expressing the neurotoxic C-terminus of β-amyloid precursor protein
US5434050A (en)	1991-08-13	1995-07-18	Regents Of The University Of Minnesota	Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5283185A (en)	1991-08-28	1994-02-01	University Of Tennessee Research Corporation	Method for delivering nucleic acids into cells
AU669489B2 (en)	1991-09-18	1996-06-13	Affymax Technologies N.V.	Method of synthesizing diverse collections of oligomers
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
AU671093B2 (en)	1992-01-07	1996-08-15	Elan Pharmaceuticals, Inc.	Transgenic animal models for alzheimer's disease
US5679348A (en)	1992-02-03	1997-10-21	Cedars-Sinai Medical Center	Immunotherapy for recurrent HSV infections
ATE245446T1 (de)	1992-02-11	2003-08-15	Jackson H M Found Military Med	Dualer träger für immunogene konstrukte
US5314813A (en)	1992-02-19	1994-05-24	Scripps Research Institute	Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
CA2117492C (en)	1992-02-28	2009-04-07	Howard L. Weiner	Bystander suppression of autoimmune diseases
ES2131107T3 (es) *	1992-03-17	1999-07-16	Novartis Ag	Anticuerpos obtenidos mediante ingenieria genetica.
EP0561087B1 (en)	1992-03-20	1999-08-04	N.V. Innogenetics S.A.	Mutated form of the beta-amyloid precursor protein gene
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5441870A (en) *	1992-04-15	1995-08-15	Athena Neurosciences, Inc.	Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en)	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
GB9209118D0 (en)	1992-04-28	1992-06-10	Sb 120 Amsterdam Bv	Vaccine compositions
US5766846A (en)	1992-07-10	1998-06-16	Athena Neurosciences	Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en)	1992-07-10	1998-11-17	Athena Neurosciences, Inc.	Methods and compositions for the detection of soluble β-amyloid peptide
WO1994001772A1 (en)	1992-07-13	1994-01-20	The Children's Medical Center Corporation	SCREEN FOR ALZHEIMER'S DISEASE THERAPEUTICS BASED ON β-AMYLOID PRODUCTION
AU4719393A (en)	1992-07-31	1994-03-03	Medeva Holdings B.V.	Expression of recombinant fusion proteins in attenuated bacteria
US5958883A (en)	1992-09-23	1999-09-28	Board Of Regents Of The University Of Washington Office Of Technology	Animal models of human amyloidoses
KR100310939B1 (ko)	1992-10-01	2002-06-20	추후제출	태그로암호화한복합조합화학라이브러리
US5605811A (en)	1992-10-26	1997-02-25	Athena Neurosciences, Inc.	Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
JP3553592B2 (ja) *	1992-10-26	2004-08-11	ビー．シェンク，デイル	可溶性β−アミロイド・ペプチドの検出のための方法及び組成物
WO1994012629A1 (en)	1992-12-02	1994-06-09	Baylor College Of Medicine	Episomal vectors for gene therapy
DK0672142T3 (da)	1992-12-04	2001-06-18	Medical Res Council	Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
EP1308461A3 (en)	1993-01-25	2004-02-11	Takeda Chemical Industries, Ltd.	Antibodies to beta-amyloids or their derivatives and use thereof
US5955317A (en)	1993-01-25	1999-09-21	Takeda Chemical Industries, Ltd.	Antibodies to β-amyloids or their derivatives and use thereof
CA2115900A1 (en)	1993-02-22	1994-08-23	Gerald W. Becker	Pharmaceutical screens and antibodies
US5776468A (en)	1993-03-23	1998-07-07	Smithkline Beecham Biologicals (S.A.)	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5643562A (en) *	1993-03-29	1997-07-01	Queen's University Of Kingston	Method for treating amyloidosis
CA2161445C (en) *	1993-04-27	2009-06-30	Anna Efim Ladd	Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
WO1994028412A1 (en)	1993-05-28	1994-12-08	The Miriam Hospital	Composition and method for in vivo imaging of amyloid deposits
ATE215124T1 (de)	1993-07-30	2002-04-15	Medeva Holdings Bv	Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
DE69429072T2 (de) *	1993-08-10	2002-07-18	Sony Corp., Tokio/Tokyo	Aufzeichnungs- und/oder wiedergabegerät
US5728385A (en) *	1993-08-12	1998-03-17	Classen Immunotherapies, Inc.	Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
WO1995005853A1 (en)	1993-08-26	1995-03-02	The Regents Of The University Of California	Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
PT735893E (pt)	1993-09-14	2009-03-06	Pharmexa Inc	Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária
US5446650A (en) *	1993-10-12	1995-08-29	Tektronix, Inc.	Logic signal extraction
CA2174501A1 (en)	1993-10-20	1995-04-27	Warren J. Strittmatter	Method of binding material to the .beta.-amyloid peptide
CA2175587A1 (en)	1993-11-02	1995-05-11	Jeffrey H. Sugarman	Synthesizing and screening molecular diversity
US5744368A (en)	1993-11-04	1998-04-28	Research Foundation Of State University Of New York	Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
US5434170A (en)	1993-12-23	1995-07-18	Andrulis Pharmaceuticals Corp.	Method for treating neurocognitive disorders
US5877218A (en)	1994-01-10	1999-03-02	Teva Pharmaceutical Industries, Ltd.	Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5877399A (en)	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
CA2182311A1 (en)	1994-01-27	1995-08-03	Karen Hsiao	Transgenic non-human mammals with progressive neurologic disease
WO1995020979A1 (en)	1994-02-03	1995-08-10	The Picower Institute For Medical Research	Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
CA2189634A1 (en)	1994-05-06	1995-11-16	John J. Baldwin	Combinatorial dihydrobenzopyran library
AU686818B2 (en) *	1994-05-25	1998-02-12	John Mcmichael	Materials and methods for treatment of plaquing diseases
US5505947A (en)	1994-05-27	1996-04-09	The University Of North Carolina At Chapel Hill	Attenuating mutations in Venezuelan Equine Encephalitis virus
US5622701A (en)	1994-06-14	1997-04-22	Protein Design Labs, Inc.	Cross-reacting monoclonal antibodies specific for E- and P-selectin
US5663046A (en)	1994-06-22	1997-09-02	Pharmacopeia, Inc.	Synthesis of combinatorial libraries
US6417178B1 (en)	1994-07-19	2002-07-09	University Of Pittsburgh	Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6114133A (en)	1994-11-14	2000-09-05	Elan Pharmaceuticals, Inc.	Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en)	1994-12-16	1997-11-18	Ramot University Authority For Applied Research And Development Ltd.	Prevention of protein aggregation
US5786180A (en)	1995-02-14	1998-07-28	Bayer Corporation	Monoclonal antibody 369.2B specific for β A4 peptide
JPH11514333A (ja)	1995-03-14	1999-12-07	プレーシスファーマスーティカルズインコーポレイテッド	アミロイドの凝集の調節剤
US7153510B1 (en)	1995-05-04	2006-12-26	Yale University	Recombinant vesiculoviruses and their uses
DE19518147B4 (de) *	1995-05-17	2013-09-05	Günther Nath	UV-stabiler Flüssigkeitslichtleiter
WO1996039176A1 (en)	1995-06-05	1996-12-12	Brigham & Women's Hospital	USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
US5948763A (en)	1995-06-07	1999-09-07	New York University	Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
ATE214603T1 (de)	1995-06-30	2002-04-15	American Cyanamid Co	Stabile makrolide und makrolide imptstoff- zusammensetzungen
US5671500A (en) *	1995-08-07	1997-09-30	Balk; Brett	Overhead door spring shield system
US5824322A (en)	1995-08-21	1998-10-20	Cytrx Corporation	Compositions and methods for growth promotion
JP3713074B2 (ja)	1995-08-30	2005-11-02	栄研化学株式会社	血清アミロイドａを認識するモノクローナル抗体
JP3495738B2 (ja)	1995-09-14	2004-02-09	ザレジェンツオブザユニバーシティーオブカリフォルニア	天然ＰｒＰｓｃ特異的抗体
US5750361A (en)	1995-11-02	1998-05-12	The Regents Of The University Of California	Formation and use of prion protein (PRP) complexes
CA2235226A1 (en)	1995-11-10	1997-05-15	Elan Corporation, Plc	Peptides which enhance transport across tissues and methods of identifying and using the same
WO1997021728A1 (en)	1995-12-12	1997-06-19	Karolinska Innovations Ab	PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b)
JPH09178743A (ja)	1995-12-27	1997-07-11	Oriental Yeast Co Ltd	可溶性ａｐｐの定量法
US6150091A (en)	1996-03-06	2000-11-21	Baylor College Of Medicine	Direct molecular diagnosis of Friedreich ataxia
US6372225B1 (en)	1996-03-23	2002-04-16	The Research Foundation Of Microbial Diseases Of Osaka University	Tetanus toxin functional fragment antigen and tetanus vaccine
CA2183901A1 (en)	1996-08-22	1998-02-23	Johanna E. Bergmann	Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6057367A (en)	1996-08-30	2000-05-02	Duke University	Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6797495B2 (en)	1996-11-05	2004-09-28	The Regents Of The University Of California	Somatic cells with ablated PrP gene and methods of use
DK1005368T3 (da)	1997-03-10	2010-01-04	Ottawa Hospital Res Inst	Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
ES2205462T3 (es)	1997-03-31	2004-05-01	Alza Corporation	Sistema de suministro por dufusion, implantable.
EP2006303A1 (en) *	1997-04-09	2008-12-24	Intellect Neurosciences, Inc.	Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof
US8173127B2 (en) *	1997-04-09	2012-05-08	Intellect Neurosciences, Inc.	Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US5972269A (en)	1997-06-17	1999-10-26	Taurus International Manufacturing, Inc.	Method of forming cavities in ceramic or metal injection molded parts using a fugitive core
WO1999000150A2 (en)	1997-06-27	1999-01-07	Regents Of The University Of California	Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
IT1293511B1 (it)	1997-07-30	1999-03-01	Gentili Ist Spa	Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
DE69842048D1 (de)	1997-08-01	2011-01-27	Max Planck Gesellschaft	Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein-aggregaten
US6004925A (en) *	1997-09-29	1999-12-21	J. L. Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US7964192B1 (en) *	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
TWI239847B (en) *	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6923964B1 (en)	1997-12-02	2005-08-02	Neuralab Limited	Active immunization of AScr for prion disorders
DE1033998T1 (de)	1997-12-03	2001-05-23	Brigham And Women's Hospital, Boston	Methode zur unterdrückung von beta-amyloid-verwandten veränderungen in alzheimer
NZ504711A (en)	1997-12-03	2002-02-01	Fujisawa Pharmaceutical Co	Soft-pellet drug and process for the preparation thereof
FR2777015B3 (fr)	1998-02-23	2000-09-15	Financ De Biotechnologie	Procede et moyens pour l'obtention de modeles cellulaires et animaux de maladies neurodegeneratives
NO314086B1 (no)	1998-05-08	2003-01-27	Gemvax As	Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
CA2328612A1 (en)	1998-05-19	1999-11-25	Yeda Research And Development Co., Ltd.	Activated t cells, nervous system-specific antigens and their uses
EP1078005B1 (en)	1998-05-21	2010-04-21	University Of Tennessee Research Foundation	Methods for amyloid removal using anti-amyloid antibodies
US20030147882A1 (en) *	1998-05-21	2003-08-07	Alan Solomon	Methods for amyloid removal using anti-amyloid antibodies
ES2216509T3 (es)	1999-01-19	2004-10-16	PHARMACIA & UPJOHN COMPANY	Procedimiento de envasado para sustancias medicinales sensibles a la oxidacion.
AU775525B2 (en) *	1999-01-22	2004-08-05	Auckland Technology Enabling Corporation Limited	Vaccine-mediated treatment of neurological disorders
PE20010212A1 (es)	1999-06-01	2001-02-22	Neuralab Ltd	Composiciones del peptido a-beta y procesos para producir las mismas
UA81216C2 (en)	1999-06-01	2007-12-25		Prevention and treatment of amyloid disease
DK1409654T3 (da)	1999-06-16	2008-12-08	Boston Biomedical Res Inst	Immunologisk styring af beta-amyloid-niveauer in vivo
US6294171B2 (en)	1999-09-14	2001-09-25	Milkhaus Laboratory, Inc.	Methods for treating disease states comprising administration of low levels of antibodies
WO2001039796A2 (en)	1999-11-29	2001-06-07	Neurochem Inc.	Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
IL149976A0 (en)	1999-12-08	2002-12-01	Mindset Biopharmaceuticals Usa	Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
US20030086938A1 (en)	2000-02-21	2003-05-08	Jensen Martin Roland	Novel methods for down-regulation of amyloid
DE1257584T1 (de)	2000-02-24	2003-05-28	Lilly Co Eli	Humanisierte antikörper, die amyloid beta peptid demarkieren
CA2404237C (en)	2000-04-05	2010-01-26	University Of Tennessee Research Corporation	Methods of investigating, diagnosing, and treating amyloidosis
PT1284998E (pt)	2000-05-22	2005-06-30	Univ New York	Eptideos imunogenicos sinteticos mas nao-amiloidogenicos homologos a beta-amiloides, destinados a induzir uma reaccao imunitaria contra os beta-amiloides e os depositos amiloides
EP2082749A3 (en)	2000-07-07	2010-06-30	Bioarctic Neuroscience AB	Prevention and treatment of Alzheimer's disease
US20020009445A1 (en)	2000-07-12	2002-01-24	Yansheng Du	Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
EP1172378A1 (en)	2000-07-12	2002-01-16	Richard Dr. Dodel	Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
IT1319277B1 (it)	2000-10-24	2003-09-26	Chiesi Farma Spa	Proteine di fusione utili per il trattamento di immunizzazione dellamalattia di alzheimer.
IL139308A0 (en)	2000-10-26	2001-11-25	Marikovsky Moshe	Peptides from amyloid precursor protein which inhibit tumor growth and metastasis
US6900036B2 (en)	2000-12-27	2005-05-31	University Of Texas Health Science Center Houston	Prion isomers, methods of making, methods of using, and compositions and products comprising prion isomers
US20020147882A1 (en) *	2001-04-10	2002-10-10	Pua Khein Seng	Universal serial bus flash memory storage device
DE60121729T2 (de)	2001-04-19	2007-11-29	Dr. Hermann Schätzl	Prion Proteindimere für Impfungen
AU2002345843A1 (en)	2001-06-22	2003-01-08	Panacea Pharmaceuticals, Inc.	Compositions and methods for preventing protein aggregation in neurodegenerative diseases
ES2435741T3 (es) *	2001-08-06	2013-12-23	Kao Corporation	Composición acondicionadora
US6953840B2 (en) *	2002-07-30	2005-10-11	Esperion Therapeutics, Inc.	Methods of using non-human animal Apolipoprotein A-I protein
CA2735869C (en) *	2008-09-18	2020-08-18	Cedars-Sinai Medical Center	Optical method for the detection of alzheimer's disease

2000
- 2000-01-06 UA UA2001118223A patent/UA81216C2/uk unknown
- 2000-06-01 AU AU53163/00A patent/AU5316300A/en not_active Abandoned
- 2000-06-01 HR HR20010893A patent/HRP20010893A2/hr not_active Application Discontinuation
- 2000-06-01 HU HU0201205A patent/HU229986B1/hu unknown
- 2000-06-01 KR KR1020097012115A patent/KR20090071673A/ko not_active Withdrawn
- 2000-06-01 SK SK1718-2001A patent/SK288207B6/sk not_active IP Right Cessation
- 2000-06-01 CZ CZ20014154A patent/CZ302971B6/cs not_active IP Right Cessation
- 2000-06-01 PT PT00938075T patent/PT1185296E/pt unknown
- 2000-06-01 AT AT00938075T patent/ATE495755T1/de active
- 2000-06-01 NZ NZ556622A patent/NZ556622A/en not_active IP Right Cessation
- 2000-06-01 EP EP00938075A patent/EP1185296B1/en not_active Expired - Lifetime
- 2000-06-01 CN CNA2007101032809A patent/CN101091795A/zh active Pending
- 2000-06-01 CN CN00808358A patent/CN1377278A/zh active Pending
- 2000-06-01 IL IL14656300A patent/IL146563A0/xx unknown
- 2000-06-01 WO PCT/US2000/015239 patent/WO2000072876A2/en not_active Ceased
- 2000-06-01 PL PL352717A patent/PL202217B1/pl unknown
- 2000-06-01 MX MXPA01012293A patent/MXPA01012293A/es active IP Right Grant
- 2000-06-01 KR KR1020017015508A patent/KR100930559B1/ko not_active Expired - Lifetime
- 2000-06-01 KR KR1020107019313A patent/KR101142772B1/ko not_active Expired - Lifetime
- 2000-06-01 BR BR0011103-1A patent/BR0011103A/pt not_active Application Discontinuation
- 2000-06-01 SG SG200401386-8A patent/SG147275A1/en unknown
- 2000-06-01 DE DE60045550T patent/DE60045550D1/de not_active Expired - Lifetime
- 2000-06-01 NZ NZ587223A patent/NZ587223A/en not_active IP Right Cessation
- 2000-06-01 CA CA2375104A patent/CA2375104C/en not_active Expired - Fee Related
- 2000-06-01 SG SG200401385-0A patent/SG147274A1/en unknown
- 2000-06-01 EA EA200101250A patent/EA200101250A1/ru unknown
- 2000-06-01 ES ES00938075T patent/ES2362029T3/es not_active Expired - Lifetime
- 2000-06-01 ES ES10182493.6T patent/ES2445799T3/es not_active Expired - Lifetime
- 2000-06-01 HK HK02106697.1A patent/HK1045117B/en not_active IP Right Cessation
- 2000-06-01 EE EEP200100645A patent/EE05492B1/et unknown
- 2000-06-01 TR TR2001/03469T patent/TR200103469T2/xx unknown
- 2000-06-01 EP EP10182493.6A patent/EP2364719B1/en not_active Expired - Lifetime
2001
- 2001-11-19 IL IL146563A patent/IL146563A/en not_active IP Right Cessation
- 2001-11-21 IS IS6170A patent/IS2925B/is unknown
- 2001-11-23 ZA ZA200109662A patent/ZA200109662B/en unknown
- 2001-11-23 BG BG106140A patent/BG65756B1/bg unknown
- 2001-11-26 NO NO20015758A patent/NO20015758L/no not_active Application Discontinuation
2007
- 2007-08-20 US US11/842,046 patent/US7977316B2/en not_active Expired - Fee Related
- 2007-08-20 US US11/842,052 patent/US8124081B2/en not_active Expired - Fee Related
2009
- 2009-03-13 US US12/403,414 patent/US20090285822A1/en not_active Abandoned
- 2009-03-30 US US12/414,347 patent/US20090285809A1/en not_active Abandoned
2010
- 2010-07-22 IL IL207166A patent/IL207166A/en not_active IP Right Cessation
- 2010-11-05 US US12/940,750 patent/US20110064734A1/en not_active Abandoned
2011
- 2011-02-23 US US13/033,336 patent/US20110177066A1/en not_active Abandoned
- 2011-02-23 US US13/033,418 patent/US20110182893A1/en not_active Abandoned
- 2011-04-18 US US13/088,983 patent/US20110287049A1/en not_active Abandoned
- 2011-04-19 CY CY20111100403T patent/CY1111639T1/el unknown

Also Published As

Publication number	Publication date
KR20100099355A (ko)	2010-09-10
UA81216C2 (en)	2007-12-25
EP1185296A2 (en)	2002-03-13
ZA200109662B (en)	2003-05-23
EA200101250A1 (ru)	2002-06-27
IL207166A0 (en)	2010-12-30
US20090285809A1 (en)	2009-11-19
CA2375104A1 (en)	2000-12-07
WO2000072876A3 (en)	2001-05-03
HUP0201205A3 (en)	2004-07-28
CZ20014154A3 (cs)	2002-11-13
HUP0201205A2 (en)	2002-08-28
IS6170A (is)	2001-11-21
US7977316B2 (en)	2011-07-12
EP2364719A1 (en)	2011-09-14
KR20020025884A (ko)	2002-04-04
HRP20010893A2 (en)	2003-04-30
US8124081B2 (en)	2012-02-28
CA2375104C (en)	2013-12-24
HK1160392A1 (en)	2012-08-17
US20110287049A1 (en)	2011-11-24
BG65756B1 (bg)	2009-10-30
TR200103469T2 (tr)	2002-05-21
EP1185296B1 (en)	2011-01-19
ES2362029T3 (es)	2011-06-27
SG147275A1 (en)	2008-11-28
CN101091795A (zh)	2007-12-26
AU5316300A (en)	2000-12-18
SG147274A1 (en)	2008-11-28
NO20015758D0 (no)	2001-11-26
EP2364719B1 (en)	2013-11-13
KR20090071673A (ko)	2009-07-01
KR101142772B1 (ko)	2012-05-18
NO20015758L (no)	2002-01-30
US20090285822A1 (en)	2009-11-19
HU229986B1 (en)	2015-04-28
SK17182001A3 (sk)	2002-09-10
IL207166A (en)	2013-11-28
CY1111639T1 (el)	2015-10-07
NZ587223A (en)	2011-12-22
BG106140A (bg)	2002-08-30
HK1045117A1 (en)	2002-11-15
CN1377278A (zh)	2002-10-30
MXPA01012293A (es)	2002-11-07
BR0011103A (pt)	2002-03-19
PL202217B1 (pl)	2009-06-30
ATE495755T1 (de)	2011-02-15
PL352717A1 (en)	2003-09-08
HK1045117B (en)	2011-08-05
DE60045550D1 (de)	2011-03-03
KR100930559B1 (ko)	2009-12-09
US20110182893A1 (en)	2011-07-28
US20110177066A1 (en)	2011-07-21
IL146563A (en)	2010-11-30
ES2445799T3 (es)	2014-03-05
NZ556622A (en)	2009-03-31
EE05492B1 (et)	2011-12-15
IS2925B (is)	2015-06-15
IL146563A0 (en)	2002-07-25
US20080248029A1 (en)	2008-10-09
WO2000072876A2 (en)	2000-12-07
US20110064734A1 (en)	2011-03-17
CZ302971B6 (cs)	2012-01-25
SK288207B6 (sk)	2014-07-02
PT1185296E (pt)	2011-04-19
US20080248023A1 (en)	2008-10-09

Publication	Publication Date	Title
EE200100645A (et)	2003-02-17	Amüloidogeense haiguse preventsioon ja ravi
CY1105922T1 (el)	2011-04-06	Χρηση υποκατεστημενων παραγωγων αζετιδινονης στη θepαπεια ασθενειας alzheimer
TW264480B (et)	1995-12-01
ATE153534T1 (de)	1997-06-15	Verfahren und zusammensetzung zur behandlung von erkrankungen des zns hervorgerufen durch abnormales beta-amyloid-protein
CY1109368T1 (el)	2014-07-02	Προληψη και θεραπεια αμυλοειδογονου νοσου
NO20022531D0 (no)	2002-05-28	Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer
DE69831971D1 (de)	2006-03-02	Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
DE602004021797D1 (de)	2009-08-13	Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
DK1137410T3 (da)	2006-12-27	Hidtil ukendte 4-dedimethylaminotetracyclinderivater
DE60221665D1 (de)	2007-09-20	Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
EP1040830A4 (en)	2002-10-23	REMEDY FOR NEURODEGENERATIVE DISEASES
DE69526216D1 (de)	2002-05-08	Antifungaleverfahren und mitteln
NO20000771D0 (no)	2000-02-16	Anvendelse av fankinon for behandling av Alzheimers sykdom
DK0821969T3 (da)	2007-03-26	Medicinsk sammensætning omfattende TCF-II
FI961494L (fi)	1996-04-03	Farmaseuttisia koostumuksia ja niiden käyttö, etenkin hermoston rappeutumissairauksien hoitamiseksi
DE60004093D1 (de)	2003-08-28	Pharmazeutische zusammensetzung welche riluzol und gabapentin enthält zur behandung von motoneuronalen krankheiten
DK8893D0 (da)	1993-01-26	Medicament for treatment or prevention of disease

Legal Events

Date	Code	Title	Description
2008-08-15	GB1A	Change in the ownership or in the address of the owner
2013-06-17	GB1A	Change in the ownership or in the address of the owner